Safety and Efficacy Study of the Nile PAX Drug-Eluting Coronary Bifurcation Stent

Inclusion Criteria: * De novo bifurcation lesions following the Medina classification except (0,0,1). * Maximum one bifurcation lesion per patient. * Single bifurcation lesion per vessel. * The patient is at least 18 years of age. The patient has clinical evidence of ischemic heart disease, stable or unstable angina, silent ischemia, or a positive functional trial. * The patient is an acceptable candidate for percutaneous transluminal coronary angioplasty (PTCA), stenting, and emergent coronary artery bypass graft (CABG) surgery. * The patient or patient's legal representative has been informed of the nature of the trial and agrees to its provisions and has provided written informed consent as approved by the Institutional Review Board/Ethics Committee (IRB/EC) of the respective clinical site. * The patient agrees to return to the same research facility for all required post-procedure follow-up visits. Exclusion Criteria: * De novo bifurcation lesion Medina (0,0,1). * Left main bifurcation. * Heavily calcified lesions. * Severe tortuous lesions. * Documented left ventricular ejection fraction (LVEF) \< 30% at most recent evaluation. * Women of childbearing potential. * Chronic total occlusion (CTO). * Previous PCI of the target lesion. * Second lesion requiring treatment in target vessel. * Second bifurcation lesion requiring treatment. * Currently participating in an investigational drug or another device trial that has not completed the primary endpoint or that clinicall…